Our goal is to be the leading global biopharmaceutical company focused on the innovative treatment of women’s health and endocrine diseases in areas of high unmet medical need, and improve the lives of millions of patients suffering from these diseases.
Our lead program is relugolix, which has been evaluated in over 1,300 patients to date. Relugolix has successfully demonstrated significant clinical benefit and was generally well-tolerated across large, randomized Phase 2 clinical trials in patients with uterine fibroids, endometriosis and prostate cancer. In addition, we are developing MVT-602 for the treatment of female infertility as part of assisted reproduction. Over time, we intend to expand our development pipeline to include other potential treatments for endocrine-related disorders.
